Dr Reddy'S Laboratories Ltd
RDY
ISIN US2561352038 / Valor 1221723
Dr Reddy'S Laboratories Ltd
UMushroom community rating:
About company
Dr. Reddy's Laboratories Ltd is a global pharmaceutical company headquartered in India, engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates through various business segments including Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars, and over-the-counter (OTC) pharmaceutical products. Dr. Reddy's has a strong focus on meeting patient needs in several therapeutic areas such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. In addition to its existing product portfolio, the company is actively developing a pipeline of novel small molecules in immuno-oncology and working on differentiated products that aim to improve upon existing therapeutic agents. Furthermore, Dr. Reddy's is investing in emerging fields like digital therapeutics, cell, and gene therapies, indicating its commitment to innovation and addressing unmet medical needs.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Revenue Growth
Dr Reddy's Laboratories Ltd reported consolidated revenues of ₹70.8 billion for Q4 FY24, reflecting a year-over-year (YoY) growth of 12% and a quarter-over-quarter (QoQ) decline of 2%. The YoY growth was primarily driven by increased revenues in global generics, particularly in North America and Emerging Markets. For the full fiscal year FY24, the company achieved consolidated revenues of ₹279.2 billion, marking a YoY growth of 14%.
Profit Margins
In Q4 FY24, Dr Reddy's Laboratories Ltd achieved a gross margin of 58.6%, consistent with the previous quarter. The profit before tax for the quarter stood at ₹16,016 million, a YoY increase of 21% but a QoQ decline of 12%. The profit after tax for Q4 FY24 was ₹13,070 million, up 36% YoY but down 5% QoQ. For the full year FY24, the profit after tax was ₹55,684 million, reflecting a YoY growth of 24%.
Segment Performance
Dr Reddy's Laboratories Ltd's Global Generics segment reported revenues of ₹61.2 billion for Q4 FY24, a YoY growth of 13% but a QoQ decline of 3%. The North America segment saw a significant YoY growth of 29%, contributing ₹32,626 million to the total revenues. However, the India segment experienced a YoY decline of 12%, with revenues of ₹11,265 million for the quarter.
Research and Development
Dr Reddy's Laboratories Ltd invested ₹6,877 million in research and development (R&D) during Q4 FY24, which is 9.7% of the total revenues. For the full year FY24, the R&D expenses amounted to ₹22,873 million, representing 8.2% of the total revenues. The company continues to focus on building its pipeline and future growth drivers through significant R&D investments.
EBITDA and Earnings
Dr Reddy's Laboratories Ltd reported an EBITDA of ₹18,720 million for Q4 FY24, which is 26.4% of the total revenues. This represents a YoY increase of 21% but a QoQ decline of 12%. For the full year FY24, the EBITDA was ₹83,013 million, accounting for 29.7% of the total revenues, reflecting a YoY growth of 19%. The diluted earnings per share (EPS) for Q4 FY24 was ₹78.35, up from ₹57.62 in Q4 FY23.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
13125 M
Market cap (USD)
26,024
Daily traded volume (Shares)
79.39 / 78.65
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
